FYN
ENSG00000010810
Target class
Kinase
Chromosome
6
Approved drugs
1
Clinical candidates (approved and in development)
6
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 6
- Chemical probe available
- Yes
- Target name
- FYN
- Gene name
- FYN proto-oncogene, Src family tyrosine kinase
- Gene symbol
- FYN
- Protein name
- Tyrosine-protein kinase Fyn (EC 2.7.10.2) (Proto-oncogene Syn) (Proto-oncogene c-Fyn) (Src-like kinase) (SLK) (p59-Fyn)
- SYN
- SLK
- MGC45350
- Gene biotype
- Protein coding
- Gene family
- SH2 domain containing|Src family tyrosine kinases
- Target class
- Kinase
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 71.31
- Tissue specificity (Gini)
- 0.319
- Tissue specificity (tau)
- 0.558
- KEGG gene identifiers
- hsa:2534
- Protein interaction confidence
- 0.875526
- Protein interaction partners
- 171
- R-HSA-114604
- R-HSA-1227986
- R-HSA-1257604
- R-HSA-1433557
- R-HSA-1433559
- R-HSA-164944
- R-HSA-202733
- R-HSA-2029481
- R-HSA-210990
- R-HSA-2219530
- R-HSA-2424491
- R-HSA-2682334
- R-HSA-2730905
- R-HSA-373753
- R-HSA-375165
- R-HSA-389356
- R-HSA-389357
- R-HSA-389359
- R-HSA-389513
- R-HSA-3928662
- R-HSA-3928663
- R-HSA-3928664
- R-HSA-3928665
- R-HSA-399954
- R-HSA-399955
And 16 more, listed on the interactive page.
- End position
- 111873475
- Start position
- 111660332
- Chromosome
- 6
- Strand
- Reverse
- Cytoplasm . Nucleus . Cell membrane . Perikaryon . Note=Present and active in lipid rafts (PubMed:12218089). Palmitoylation is crucial for proper trafficking (PubMed:8206991). .
- Cytosol
- Plasma membrane
- PubMed 15537652
- PubMed 8206991
- PubMed 12218089
- Tissue specificity (tau)
- 0.557589
- Expression inequality (Gini)
- 0.319122
Expression in transcripts per million
- Nerve - Tibial
- 71.31
- Adipose - Subcutaneous
- 64.23
- Brain - Cerebellar Hemisphere
- 58.85
- Lung
- 58.09
- Brain - Cerebellum
- 55.83
Expression in transcripts per million
- Nerve - Tibial71.31
- Adipose - Subcutaneous64.23
- Brain - Cerebellar Hemisphere58.85
- Lung58.09
- Brain - Cerebellum55.83
- Spleen52.82
- Adipose - Visceral (Omentum)52.51
- Brain - Frontal Cortex (BA9)51.37
- Cells - Cultured fibroblasts50.84
- Cervix - Endocervix50.78
- Brain - Amygdala50.72
- Uterus50.05
- Cervix - Ectocervix49.61
- Brain - Cortex49.55
- Brain - Anterior cingulate cortex (BA24)47.18
- Brain - Spinal cord (cervical c-1)46.7
- Brain - Nucleus accumbens (basal ganglia)45.36
- Brain - Hypothalamus43.5
- Fallopian Tube42.87
- Brain - Caudate (basal ganglia)42.25
- Brain - Hippocampus41.71
- Thyroid39.91
- Brain - Substantia nigra39.9
- Bladder38.8
- Brain - Putamen (basal ganglia)36.98
And 29 more, listed on the interactive page.
- GO:0002223
- GO:0002862
- GO:0003015
- GO:0007216
- GO:0007411
- GO:0007612
- GO:0007631
- GO:0030101
- GO:0031295
- GO:0035556
- GO:0038096
- GO:0048010
- GO:0048013
- GO:0050852
- GO:0050860
- GO:0050868
- GO:0050900
- GO:0097062
- GO:1904646
- GO:1905477
- GO:0005634
- GO:0005737
- GO:0005768
- GO:0005829
- GO:0005886
- GO:0030425
- GO:0045121
- GO:0001664
- GO:0004713
- GO:0004715
- GO:0005515
- GO:0016004
- GO:0019899
- GO:0042802
- GO:0043274
- GO:0046875
- GO:0048156
- GO:0070851
- GO:0097110
- GO:0097718
regulation of catalytic activity
- biochemical: NVS_ENZ_hFyn, is one of one assay component(s) measured or calculated from the NVS_ENZ_hFyn assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.
- biochemical: NVS_ENZ_hFyn, is one of one assay component(s) measured or calculated from the NVS_ENZ_hFyn assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.
Biological samples
- cell-free
Evidence source
Related records
Trials (892)
- A Bioequivalence Study of Dasatinib Tablet
- A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GIST
- A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma
- A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL)
- A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
- A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma
- A Crossover Study to Evaluate the Bioavailability of Ibrutinib Suspension and Sprinkle Formulations Compared to Capsules in Healthy Adults
- A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.
- A Drug Interaction Study Between Bosutinib And Aprepitant In Healthy Volunteers
- A Drug Interaction Study to Assess the Effect of Omeprazole on the Pharmacokinetics of Ibrutinib in Healthy Adults
- A Long-term Extension Study of PCI-32765 (Ibrutinib)
- A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas
- A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors
- A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
- A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion
- A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
- A Pharmacokinetic Study in Healthy Participants to Assess the Pharmacokinetics and Safety of a Supratherapeutic Dose of PCI-32765 (Ibrutinib) Capsule and Solution Formulations Administered With Food
- A Phase 1 Safety Study of TG100801 Eye Drops in Healthy Volunteers
- A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies
- A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies
Drugs (12)
- Acalabrutinib
- Bosutinib
- Dasatinib
- Dasatinib anhydrous SRC inhibitor
- Dasatinib laurylsulfate SRC inhibitor
- ENMD-981693 SRC inhibitor
- Ibrutinib
- Ilorasertib SRC inhibitor
- JNJ-26483327 Tyrosine-protein kinase FYN inhibitor
- Pexmetinib
- TG100-801 SRC inhibitor
- XL-228 SRC inhibitor